# BCL2L2

## Overview
BCL2L2, also known as BCL-W, is a gene that encodes the BCL2 like 2 protein, a member of the BCL-2 protein family, which is integral to the regulation of apoptosis. The BCL2 like 2 protein is categorized as an anti-apoptotic protein, functioning primarily to inhibit the activity of pro-apoptotic proteins such as BAX and BAK, thereby preventing mitochondrial outer membrane permeabilization and subsequent apoptotic processes (Singh2019Regulation). Structurally, the protein is characterized by BCL-2 homology (BH) domains, which facilitate its interactions with other BCL-2 family members, and a transmembrane domain that anchors it to intracellular membranes, including the mitochondrial outer membrane (Czabotar2013Control). BCL2L2 plays a significant role in cellular homeostasis and survival, with implications in various physiological processes and pathological conditions, particularly in cancer, where its dysregulation can contribute to tumor progression and resistance to therapy (Kønig2019Alterations; Lam2012Biomarkers).

## Structure
BCL2L2, also known as BCL-W, is a member of the BCL-2 protein family involved in regulating apoptosis. The protein shares sequence homology with other BCL-2 family members, characterized by BCL-2 homology (BH) domains, specifically BH1-BH4 (Czabotar2013Control; Singh2019Regulation). These domains are crucial for its anti-apoptotic function, allowing BCL2L2 to bind and sequester pro-apoptotic proteins, thereby inhibiting apoptosis (Singh2019Regulation).

Structurally, BCL2L2 features a helical bundle surrounding a central hydrophobic core helix, forming a hydrophobic surface groove. This groove is essential for interactions with the BH3 domain of pro-apoptotic members of the BCL-2 family (Czabotar2013Control). The protein is anchored to intracellular membranes, such as the mitochondrial outer membrane, by a carboxy-terminal hydrophobic transmembrane domain (Czabotar2013Control).

BCL2L2 can form homo- or heterodimers, indicating a quaternary structure, which is important for its function in apoptosis regulation. Post-translational modifications, such as phosphorylation, can regulate its activity, potentially altering its interactions and function (Czabotar2013Control). The presence of splice variants may also influence its functional properties, although specific details on these variants are not provided in the context.

## Function
BCL2L2, also known as BCL-W, is a member of the BCL-2 protein family, which plays a crucial role in regulating apoptosis, an essential process for maintaining cellular homeostasis. BCL2L2 functions as an anti-apoptotic protein, primarily by inhibiting pro-apoptotic members of the BCL-2 family, such as BAX and BAK, thereby preventing mitochondrial outer membrane permeabilization (MOMP) and subsequent cytochrome c release, which are critical steps in the intrinsic apoptosis pathway (Singh2019Regulation).

In the context of megakaryopoiesis, BCL2L2 is involved in enhancing the survival of megakaryocytes (MKs) by reducing apoptosis, which is vital for effective platelet production. Overexpression of BCL2L2 in cultured human MKs leads to increased proplatelet formation and a higher number of viable MKs, indicating its role in promoting cell survival and function (Bhatlekar2019Antiapoptotic). BCL2L2 expression is positively correlated with peripheral blood platelet counts, suggesting its involvement in regulating platelet numbers in healthy individuals (Bhatlekar2019Antiapoptotic).

BCL2L2 is active in the mitochondria, where it helps maintain mitochondrial integrity, thus playing a significant role in cell survival and the prevention of unnecessary apoptosis (Singh2019Regulation).

## Clinical Significance
Alterations in the expression and interactions of the BCL2L2 gene, also known as BCL-W, have significant clinical implications, particularly in cancer. BCL2L2 is part of the BCL-2 family, which plays a crucial role in regulating apoptosis. Dysregulation of BCL2L2 can contribute to cancer development by inhibiting apoptosis and promoting cell survival, leading to tumor progression and resistance to chemotherapy (Lam2012Biomarkers).

In various cancers, including breast and gynaecologic cancers, BCL2L2 expression is often downregulated, which may be due to miRNA activity or other regulatory mechanisms (Kønig2019Alterations; Wang2020B‐cell). This downregulation is associated with the spatial and temporal heterogeneity of BCL2 family genes in cancer, affecting their role in apoptosis regulation (Wang2020B‐cell).

The differential expression of BCL2L2 and its interactions with other BCL-2 family members are significant in the context of breast cancer, where it is downregulated in certain subtypes, potentially impacting the balance between cell survival and apoptosis (Kønig2019Alterations). Understanding these alterations is crucial for developing targeted therapies, as BCL2L2 and other BCL-2 family proteins are important therapeutic targets in cancer treatment (Lam2012Biomarkers).

## Interactions
BCL2L2, also known as Bcl-w, is a pro-survival member of the Bcl-2 protein family that plays a crucial role in regulating apoptosis through its interactions with other proteins. BCL2L2 interacts with pro-apoptotic proteins such as BAX and BAK, inhibiting their oligomerization and preventing mitochondrial outer membrane permeabilization, a critical step in the apoptosis pathway (Singh2019Regulation). This interaction occurs through the binding of the hydrophobic face of the BH3 domain on pro-apoptotic proteins into a hydrophobic groove formed by the BH1-BH3 domains on BCL2L2 (Singh2019Regulation).

BCL2L2 is part of a complex interaction network involving 22 direct interactions with other proteins, as identified in a study analyzing the Bcl-2 family protein interactome (Kønig2019Alterations). This network includes interactions with BH3-only proteins, which are crucial for the regulation of apoptosis. BCL2L2 is part of the main component of this network, which includes most Bcl-2 family members and BH3-only proteins, highlighting its role as a hub in apoptosis regulation (Kønig2019Alterations). These interactions are significant in the context of cancer, particularly breast cancer, where alterations in the Bcl-2 protein interactome can impact apoptosis regulation (Kønig2019Alterations).


## References


[1. (Singh2019Regulation) Rumani Singh, Anthony Letai, and Kristopher Sarosiek. Regulation of apoptosis in health and disease: the balancing act of bcl-2 family proteins. Nature Reviews Molecular Cell Biology, 20(3):175–193, January 2019. URL: http://dx.doi.org/10.1038/s41580-018-0089-8, doi:10.1038/s41580-018-0089-8. This article has 1291 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41580-018-0089-8)

[2. (Lam2012Biomarkers) Lloyd T. Lam, Haichao Zhang, and Brenda Chyla. Biomarkers of therapeutic response to bcl2 antagonists in cancer. Molecular Diagnosis &amp; Therapy, 16(6):347–356, September 2012. URL: http://dx.doi.org/10.1007/s40291-012-0003-6, doi:10.1007/s40291-012-0003-6. This article has 12 citations.](https://doi.org/10.1007/s40291-012-0003-6)

[3. (Bhatlekar2019Antiapoptotic) Seema Bhatlekar, Indranil Basak, Leonard C. Edelstein, Robert A. Campbell, Cory R. Lindsey, Joseph E. Italiano, Andrew S. Weyrich, Jesse W. Rowley, Matthew T. Rondina, Martha Sola-Visner, and Paul F. Bray. Anti-apoptotic bcl2l2 increases megakaryocyte proplatelet formation in cultures of human cord blood. Haematologica, 104(10):2075–2083, February 2019. URL: http://dx.doi.org/10.3324/haematol.2018.204685, doi:10.3324/haematol.2018.204685. This article has 23 citations.](https://doi.org/10.3324/haematol.2018.204685)

4. (Kønig2019Alterations) Alterations of the pro-survival Bcl-2 protein interactome in breast cancer at the transcriptional, mutational and structural level. This article has 7 citations.

[5. (Wang2020B‐cell) Jiajian Wang, Sidi Li, Shudai Lin, Shuying Fu, Li Qiu, Ke Ding, Keying Liang, and Hongli Du. B‐cell lymphoma 2 family genes show a molecular pattern of spatiotemporal heterogeneity in gynaecologic and breast cancer. Cell Proliferation, May 2020. URL: http://dx.doi.org/10.1111/cpr.12826, doi:10.1111/cpr.12826. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.1111/cpr.12826)

[6. (Czabotar2013Control) Peter E. Czabotar, Guillaume Lessene, Andreas Strasser, and Jerry M. Adams. Control of apoptosis by the bcl-2 protein family: implications for physiology and therapy. Nature Reviews Molecular Cell Biology, 15(1):49–63, December 2013. URL: http://dx.doi.org/10.1038/nrm3722, doi:10.1038/nrm3722. This article has 2300 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/nrm3722)